Identification of breast cancer DNA methylation markers optimized for fine-needle aspiration samples

Cancer Epidemiology Biomarkers and Prevention

Volumn 22, Issue 12, 2013, Pages 2212-2221

  Bu, Dawei ^a   Lewis, Cheryl M ^a   Sarode, Venetia ^a   Chen, Min ^b   Ma, Xiaotu ^c   Lazorwitz, Aaron M ^a   Rao, Roshni ^a   Leitch, Marilyn ^a   Moldrem, Amy ^a   Andrews, Valerie ^a   Gazdar, Adi ^a   Euhus, David ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; BRCA1 PROTEIN; CLAUDIN 1; CXCL14 CHEMOKINE; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HLA B ANTIGEN; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; PROTEIN P53;

ADULT; AGED; ARTICLE; BREAST BIOPSY; BREAST CANCER; CANCER SIZE; CELL STRAIN MCF 7; DNA METHYLATION; FINE NEEDLE ASPIRATION BIOPSY; GENE EXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY, FINE-NEEDLE; BREAST NEOPLASMS; CELL LINE, TUMOR; DNA METHYLATION; DNA, NEOPLASM; FEMALE; GENE EXPRESSION; HUMANS; MIDDLE AGED; TUMOR MARKERS, BIOLOGICAL;

EID: 84890033656     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-13-0208     Document Type: Article

References (44)

1. Fabian CJ, Kimler BF, Zalles CM, Klemp JR, Petroff BK, Khan QJ, et al. Reduction in Ki-67 in benign breast tissue of high-risk women with the lignan secoisolariciresinol diglycoside. Cancer Prev Res (Phila) 2010;3:1342-50.
2. Bartels PH, Fabian CJ, Kimler BF, Ranger-Moore JR, Frank DH, Yozwiak ML, et al. Karyometry of breast epithelial cells acquired by random periareolar fine needle aspiration in women at high risk for breast cancer. Anal Quant Cytol Histol 2007;29:63-70.
3. Fabian CJ, Kimler BF, Zalles CM, Khan QJ, Mayo MS, Phillips TA, et al. Reduction in proliferation with six months of letrozole in women on hormone replacement therapy. Breast Cancer Res Treat 2007;106: 75-84.
4. Fabian CJ, Kimler BF, Brady DA, Mayo MS, Chang CH, Ferraro JA, et al. A phase II breast cancer chemoprevention trial of oral alpha- difluoromethylornithine: breast tissue, imaging, and serum and urine biomarkers. Clin Cancer Res 2002;8:3105-17.
5. Khan SA, Chatterton RT, Michel N, Bryk M, Lee O, Ivancic D, et al. Soy isoflavone supplementation for breast cancer risk reduction: a randomized phase II trial. Cancer Prev Res (Phila) 2012;5:309-19.
6. Baker JC Jr, Ostrander JH, Lem S, Broadwater G, Bean GR, D'Amato NC, et al. ESR1 promoter hypermethylation does not predict atypia in RPFNA nor persistent atypia after 12 months tamoxifen chemoprevention. Cancer Epidemiol Biomarkers Prev 2008;17:1884-90.
7. Euhus D, Bu D, Xie XJ, Sarode V, Ashfaq R, Hunt K, et al. Tamoxifen downregulates ets oncogene family members ETV4 and ETV5 in benign breast tissue: implications for durable risk reduction. Cancer Prev Res (Phila) 2011;4:1852-62.
8. Novak P, Jensen TJ, Garbe JC, Stampfer MR, Futscher BW. Stepwise DNA methylation changes are linked to escape from defined proliferation barriers and mammary epithelial cell immortalization. Cancer Res 2009;69:5251-8.
9. Umbricht CB, Evron E, Gabrielson E, Ferguson A, Marks J, Sukumar S. Hypermethylation of 14-3-3 sigma (stratifin) is an early event in breast cancer. Oncogene 2001;20:3348-53.
10. Tommasi S, Karm DL, Wu X, Yen Y, Pfeifer GP. Methylation of homeobox genes is a frequent and early epigenetic event in breast cancer. Breast Cancer Res 2009;11:R14.
11. Tlsty TD, Crawford YG, Holst CR, Fordyce CA, Zhang J, McDermott K, et al. Genetic and epigenetic changes in mammary epithelial cells may mimic early events in carcinogenesis. J Mammary Gland Biol Neoplasia 2004;9:263-74.
12. Vasilatos SN, Broadwater G, Barry WT, Baker JC Jr, Lem S, Dietze EC, et al. CpG island tumor suppressor promoter methylation in non-BRCA-associated early mammary carcinogenesis. Cancer Epidemiol Biomarkers Prev 2009;18:901-14.
13. Bean GR, Ibarra Drendall C, Goldenberg VK, Baker JC Jr, Troch MM, Paisie C, et al. Hypermethylation of the breast cancer-associated gene 1 promoter does not predict cytologic atypia or correlate with surrogate end points of breast cancer risk. Cancer Epidemiol Biomarkers Prev 2007;16:50-6.
14. Bean GR, Bryson AD, Pilie PG, Goldenberg V, Baker JC Jr, Ibarra C, et al. Morphologically normal-appearing mammary epithelial cells obtained from high-risk women exhibit methylation silencing of INK4a/ARF. Clin Cancer Res 2007;13:6834-41.
15. Bean GR, Scott V, Yee L, Ratliff-Daniel B, Troch MM, Seo P, et al. Retinoic acid receptor-B2 promoter methylation in random periareolar fine needle aspiration. Cancer Epi Biomark Prev 2005;14:790-8.
16. Van der Auwera I, Bovie C, Svensson C, Trinh XB, Limame R, van Dam P, et al. Quantitative methylation profiling in tumor and matched morphologically normal tissues from breast cancer patients. BMC Cancer 2010;10:97.
17. Euhus DM, Bu D, Ashfaq R, Xie XJ, Bian A, Leitch AM, et al. Atypia and DNA methylation in nipple duct lavage in relation to predicted breast cancer risk. Cancer Epidemiol Biomarkers Prev 2007;16: 1812-21.
18. Euhus DM, Bu D, Milchgrub S, Xie XJ, Bian A, Leitch AM, et al. DNA methylation in benign breast epithelium in relation to age and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2008;17:1051-9.
19. Feng W, Shen L, Wen S, Rosen DG, Jelinek J, Hu X, et al. Correlation between CpG methylation profiles and hormone receptor status in breast cancers. Breast Cancer Res 2007;9:R57.
20. Cho YH, Yazici H, Wu HC, Terry MB, Gonzalez K, Qu M, et al. Aberrant promoter hypermethylation and genomic hypomethylation in tumor, adjacent normal tissues and blood from breast cancer patients. Anticancer Res 2010;30:2489-96.
21. Lewis CM, Cler LR, Bu DW, Zochbauer-Muller S, Milchgrub S, Naftalis EZ, et al. Promoter hypermethylation in benign breast epithelium in relation to predicted breast cancer risk. Clin Cancer Res 2005;11: 166-72.
22. Van der Auwera I, Yu W, Suo L, Van Neste L, van Dam P, Van Marck EA, et al. Array-based DNA methylation profiling for breast cancer subtype discrimination. PLoS ONE [Electronic Resource] 2010;5: e12616.
23. Fackler MJ, Umbricht CB, Williams D, Argani P, Cruz LA, Merino VF, et al. Genome-wide methylation analysis identifies genes specific to breast cancer hormone receptor status and risk of recurrence. Cancer Res 2011;71:6195-207.
24. Hill VK, Ricketts C, Bieche I, Vacher S, Gentle D, Lewis C, et al. Genome-wide DNA methylation profiling of CpG islands in breast cancer identifies novel genes associated with tumorigenicity. Cancer Res 2011;71:2988-99.
25. Kamalakaran S, Varadan V, Giercksky Russnes HE, Levy D, Kendall J, Janevski A, et al. DNA methylation patterns in luminal breast cancers differ from non-luminal subtypes and can identify relapse risk independent of other clinical variables. Mol Oncol 2011;5: 77-92.
26. Holm K, Hegardt C, Staaf J, Vallon-Christersson J, Jonsson G, Olsson H, et al. Molecular subtypes of breast cancer are associated with characteristic DNA methylation patterns. Breast Cancer Res 2010; 12:R36.
27. Fang F, Turcan S, Rimner A, Kaufman A, Giri D, Morris LG, et al. Breast cancer methylomes establish an epigenomic foundation for metastasis. Sci Transl Med 2011;3:75ra25.
28. Li L, Lee KM, Han W, Choi JY, Lee JY, Kang GH, et al. Estrogen and progesterone receptor status affect genome-wide DNA methylation profile in breast cancer. Hum Mol Genet 2010;19: 4273-7.
29. Tlsty TD, Romanov SR, Kozakiewicz BK, Holst CR, Haupt LM, Crawford YG. Loss of chromosomal integrity in human mammary epithelial cells subsequent to escape from senescence. J Mammary Gland Biol Neoplasia 2001;6:235-43.
30. Genome Bioinformatics Group of UC Santa Cruz, The UCSC Genome Browser, http://genome.ucsc.edu/cgi-bin/hgGateway. Accessed August 18, 2013.
31. Jirtle RL, geneimprint, http://www.geneimprint.com/site/genes-byspecies. Accessed August 18, 2013.
32. Li LC, Dahiya R. MethPrimer: designing primers for methylation PCRs. Bioinformatics 2002;18:1427-31.
33. Premier Biosoft International, Beacon Designer, version 7.21.
34. Applied Biosystems, Methyl Primer Express, version 1.0.
35. Fackler MJ, McVeigh M, Mehrotra J, Blum MA, Lange J, Lapides A, et al. Quantitative multiplex methylation-specific PCR assay for the detection of promoter hypermethylation in multiple genes in breast cancer. Cancer Res 2004;64:4442-52.
36. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B 1995;57:289-300.
37. US Department of Health and Human Services. National Cancer Institute. The Cancer Genome Atlas. http://cancergenome.nih.gov. Accessed August 18, 2013.
38. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 1996;93:9821-6.
39. Sproul D, Nestor C, Culley J, Dickson JH, Dixon JM, Harrison DJ, et al. Transcriptionally repressed genes become aberrantly methylated and distinguish tumors of different lineages in breast cancer. Proc Natl Acad Sci U S A 2011;108:4364-9.
40. Widschwendter M, Siegmund KD, Muller HM, Fiegl H, Marth C, Muller-Holzner E, et al. Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen. Cancer Res 2004;64:3807-3813.
41. Sunami E, Shinozaki M, Sim MS, Nguyen SL, Vu AT, Giuliano AE, et al. Estrogen receptor and HER2/neu status affect epigenetic differences of tumor-related genes in primary breast tumors. Breast Cancer Res 2008;10:R46.
42. Park SY, Kwon HJ, Choi Y, Lee HE, Kim SW, Kim JH, et al. Distinct patterns of promoter CpG island methylation of breast cancer subtypes are associated with stem cell phenotypes. Mod Pathol 2012; 25:185-96.
43. Lee JS, Fackler MJ, Lee JH, Choi C, Park MH, Yoon JH, et al. Basal-like breast cancer displays distinct patterns of promoter methylation. Cancer Biol Ther 2010;9:1017-24.
44. Ronneberg JA, Fleischer T, Solvang HK, Nordgard SH, Edvardsen H, Potapenko I, et al. Methylation profiling with a panel of cancer related genes: association with estrogen receptor, TP53 mutation status and expression subtypes in sporadic breast cancer. Mol Oncol 2011; 5:61-76.